35 articles - From Saturday Jan 08 2022 to Friday Jan 14 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
| Nephrol Dial Transplant |
Rapidly progressive iga nephropathy: clinicopathological characteristics and outcomes assessed according to the revised definition of the KDIGO 2021 guideline. These data support the validity of the KDIGO 2021 definition but require independent validation in other non-Chinese cohorts. |
meta-analyses and systematic reviews
| Nephrol Dial Transplant |
RCT, clinical trials, retrospective studies, etc…
| Am J Kidney Dis |
Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank. Nonalbuminuric DKD was associated with higher risks of HHF, and CKD progression than no DKD, regardless of baseline eGFR. |
| J Am Soc Nephrol |
Gentamicin Inhibits Ca2+ Channel TRPV5 and Induces Calciuresis Independent of the Calcium-Sensing Receptor-Claudin-14 Pathway. Methods We studied the effect of gentamicin activation of the CaSR-CLDN14 pathway or by interfering with proximal tubular CLDN2-dependent Ca 2+ reabsorption. Instead, gentamicin blocks distal Ca 2+ reabsorption by direct inhibition of the Ca 2+ channel TRPV5. These findings offer new insights into Ca 2+ wasting in patients treated with gentamicin. |
Using Machine Learning to Identify Metabolomic Signatures of Pediatric Chronic Kidney Disease Etiology. ML models identified metabolomic signatures based on CKD cause. Using ML techniques in conjunction with traditional biostatistics, we demonstrated that sphingomyelin-ceramide and plasmalogen dysmetabolism are associated with FSGS and that gut microbiome-derived histidine metabolites are associated with OU. |
| Kidney Int |
Macrophage dynamics in kidney repair: elucidation of a COX-2-dependent MafB pathway to affect macrophage differentiation. recently identified a robust increase in the expression of cylocloxygenase-2 in proresolving macrophages (M2) during the repair phase of acute kidney injury. The investigators determined the prostaglandin E2 was produced in macrophages and demonstrated that signaling through the E-type prostanoid receptor 4 stimulated the expression of the anti-inflammatory transcription factor MafB. MafB was further shown to be essential for macrophage differentiation and mediation of the intrinsic repair response following experimental acute kidney injury. |
One small mouse step for man. provide kidney analyses of these knockout and wild-type mice. All spaceflight mice exhibited gene changes that could suppress levels of active vitamin D and increase blood pressure. Nuclear factor erythroid 2-related factor 2 may alter expression of genes related to lipid excretion and metabolism. |
SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time? Heerspink et al. revealed that dapagliflozin, an SGLT2 inhibitor, reduced the risk of abrupt declines in kidney function during the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial. Their findings may serve to reassure clinicians prescribing SGLT2 inhibitors to patients with chronic kidney disease. |
Therapeutic potential of Beclin1 for transition from AKI to CKD: autophagy-dependent and autophagy-independent functions. Beclin1 is a key molecule for autophagy as well as endocytosis and phagocytosis. Shi et al. demonstrate that Beclin1 activates autophagy and is a promising therapeutic target for AKI-to-CKD transition. |
| Nephrol Dial Transplant |
Barriers to conservative care from patients' and nephrologists' perspectives: The CKD-REIN Study. Although reported by nephrologists to be widely available and easily discussed, conservative care is only occasionally offered to older patients, most of whom report they were not informed of this option. The lack of a person or team responsible for conservative care and unclear information appear to be key barriers to its implementation. |
Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome. Clinical features and response to RAAS blockers were observed to be strongly correlated with the genotypes of male XLAS patients. Genotyping of COL4A5 gene mutations is essential and is a useful tool to assess the prognosis of AS patients. |
Lifelong Effect of Therapy in Young Patients with the COL4A5 Alport Missense Variant p.(Gly624Asp): a Prospective Cohort Study. For the first time, this study shows that in Alport syndrome, early therapy in individuals with missense variants might have the potential to delay renal failure for their lifetime and thus to improve life-expectancy and quality of life without the need for renal replacement therapy. Some treated patients have reached retirement age with still-functioning kidneys whereas untreated relatives have already reached ESRF at the same or younger age. Thus, in children with glomerular hematuria, early testing for Alport-related gene variants could lead to timely nephroprotective intervention. |
Overcoming barriers in the design and implementation of clinical trials for Acute Kidney Injury: a report from the 2020 Kidney Disease Clinical Trialists meeting. AKI is best understood as a syndrome, and identification of AKI subphenotypes is needed to elucidate the disease's myriad etiologies and tailor effective prevention and treatment strategies. Conventional RCTs are logistically cumbersome and often feature highly selected patient populations that limit external generalizability, and thus alternative trial designs should be considered when appropriate. In this narrative review of recent developments in AKI trials based on the Kidney Disease Clinical Trialists (KDCT) 2020 meeting, we discuss barriers to and strategies for improved design and implementation of clinical trials for AKI patients, including predictive and prognostic enrichment techniques, the use of pragmatic trials, and adaptive trials. |
RtNet: a deep hybrid neural networks for the identification of acute rejection and chronic allograft nephropathy after renal transplantation using multiparametric MRI. Our study revealed that the proposed RtNet+ model owned a stable performance in revealing the cause of renal allograft dysfunction, thus might afford important references for individualized diagnostics and treatment strategy. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Am J Kidney Dis |
Antifibrotic Agents for the Management of CKD: A Review. However, any future drug targeting fibrosis of the kidneys should demonstrate added benefit to a novel standard of care combining renin-angiotensin system with mineralocorticoid receptor (e. g. finerenone) blockade or with SGLT2 inhibitors. |
| J Am Soc Nephrol |
Mechanisms and Models of Kidney Tubular Necrosis and Nephron Loss. Here, we argue that a molecular switch downstream of tubular necrosis determines nephron regeneration versus nephron loss. Unraveling the details of this "switch" must include the inflammatory response to tubular necrosis and regenerative signals potentially controlled by inflammatory cells, including the stimulation of myofibroblasts as the origin of fibrosis. Understanding in detail the molecular switch and the inflammatory responses to tubular necrosis can inform the discussion of therapeutic options. |
| Nat Rev Nephrol |
Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Diagnosis of MAFLD is based on evidence of hepatic steatosis (as assessed by liver biopsy, imaging techniques or blood biomarkers and scores) in persons who are overweight or obese and have type 2 diabetes mellitus or metabolic dysregulation, regardless of the coexistence of other liver diseases or excessive alcohol consumption. The known association between NAFLD and chronic kidney disease (CKD) and our understanding that CKD can occur as a consequence of metabolic dysfunction suggests that individuals with MAFLD - who by definition have fatty liver and metabolic comorbidities - are at increased risk of CKD. In this Perspective article, we discuss the clinical associations between MAFLD and CKD, the pathophysiological mechanisms by which MAFLD may increase the risk of CKD and the potential drug treatments that may benefit both conditions. |
Letters to the editors and authors’ replies
| Am J Kidney Dis |
| Clin J Am Soc Nephrol |
| Kidney Int |
all remaining publications eg case reports, images of the month, etc…
| Kidney Int |
Expression of concern from the KI Editors: "Apolipoprotein-1 risk variants and associated kidney phenotypes in an adult HIV cohort in Nigeria" [Kidney International, July 2021, Pages 146-154] and "APOL1-associated kidney disease in northern Nigerians with treated HIV infection" [Kidney International, July 2021, Pages 19-21]. |
| Nat Rev Nephrol |
| Nephrol Dial Transplant |